Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for hormonally driven cancers. The company operates within the biotechnology and oncology drug development industries, with a primary emphasis on estrogen receptor–positive (ER+) breast cancer. Its core strategy centers on developing novel endocrine therapies designed to overcome resistance mechanisms associated with current standards of care.
The company’s lead product candidate, OP-1250 (palazestrant), is an orally available next-generation selective estrogen receptor degrader (SERD) intended to address limitations of earlier endocrine therapies. Olema was founded in 2016 and has since advanced from preclinical research to multiple clinical-stage programs, transitioning to a publicly traded company following its initial public offering in 2021. The company is headquartered in the United States and remains focused on advancing precision oncology treatments.
Business Operations
Olema’s operations are organized around a single operating segment focused on oncology drug research and development, with revenue generation currently limited as the company does not have approved commercial products. The company’s activities primarily involve clinical development, regulatory strategy, and translational research supporting its drug candidates. Research and development expenses constitute the majority of operating costs, consistent with its clinical-stage profile.
The company conducts clinical trials both domestically and internationally through third-party clinical research organizations. Olema controls intellectual property related to its proprietary SERD technology platform and associated compounds. It does not currently report material revenue from partnerships, though it maintains collaborations with academic institutions and contract research partners to support drug development activities.
Strategic Position & Investments
Olema’s strategic direction is centered on advancing OP-1250 through late-stage clinical development and expanding its pipeline of endocrine therapies for breast cancer. The company has invested significantly in clinical trials evaluating monotherapy and combination regimens, including studies combining OP-1250 with CDK4/6 inhibitors to address treatment resistance in ER+ breast cancer.
Beyond its lead program, Olema is developing additional preclinical and early clinical candidates targeting estrogen receptor biology. The company’s investment strategy prioritizes internal research and development rather than acquisitions, and it does not currently report ownership of notable subsidiaries or a diversified investment portfolio. Its positioning is differentiated by a focus on oral SERDs with improved efficacy and tolerability profiles compared to earlier agents.
Geographic Footprint
Olema Pharmaceuticals is headquartered in South San Francisco, California, within the United States, and primarily operates from this location. Its corporate, research, and administrative functions are centralized domestically, reflecting its status as a development-stage biotechnology company.
Internationally, Olema has a clinical presence across North America, Europe, and other regions through global clinical trials conducted at investigational sites outside the United States. While the company does not maintain significant physical operations abroad, its international footprint is driven by patient enrollment, regulatory engagement, and collaboration with global research partners.
Leadership & Governance
Olema is led by an experienced management team with backgrounds in oncology drug development, regulatory affairs, and biopharmaceutical commercialization. The leadership emphasizes scientific rigor, disciplined capital allocation, and a patient-focused development strategy aimed at addressing unmet needs in breast cancer treatment.
Key executives include:
- Sean Bohen – President and Chief Executive Officer
- Deborah Crawford – Chief Financial Officer
- Paul Bilic – Chief Operating Officer
- John G. Shepherd – Chief Medical Officer
- Karen J. Phipps – General Counsel and Corporate Secretary
The company is governed by a board of directors with experience across biotechnology, finance, and life sciences, supporting Olema’s long-term strategic vision and oversight as a publicly listed clinical-stage company.